Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TNFSF11 | O14788 | 3/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | CCR9 | P51686 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3132217 | 0.90 | ACLY (0.60) | ACLYALDH1A1GAALMNAHTR6 | |
| SCHEMBL3146270 | 0.89 | ACLY (0.55) | ACLYLMNAHTR6TNFSF11 | |
| Diethylamine SCHEMBL4566735 | 0.84 | ACLY (0.54) | ACLYALDH1A1GAALMNAHTR6 | |
| SCHEMBL3132165 | 0.82 | AKR1C3 (0.50) | ACLYSMN1; SMN2LMNAHTR6HSD11B1 | |
| SCHEMBL3137579 | 0.81 | FLT1 (0.46) | ACLYKDM4ESMN1; SMN2LMNAHTR6 | |
| SCHEMBL3145976 | 0.80 | HDAC1 (0.48) | ACLYHTR6TNFSF11TNF | |
| SCHEMBL3133901 | 0.80 | PLK1 (0.55) | ACLYHTR6HSD11B1CCR9 | |
| SCHEMBL3141520 | 0.77 | FLT1 (0.47) | ACLYHTR6CCR9 | |
| SCHEMBL20424520 | 0.77 | ALOX5 (0.50) | ACLYALDH1A1LMNAHTR6TNFSF11 | |
| SCHEMBL3131370 | 0.77 | FLT1 (0.47) | ACLYKDM4ESMN1; SMN2LMNAHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | claimed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| EP-2118060-B1 | 1-BENZENESULFONYL-1H-INDOLE DERIVATIVES AS INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075963-A1 | Pharmaceutically Active Benzensulphonyl-Indols | CCR9, IDO1, CCR10 | ACLY 3435/4885ALDH1A1 653/4885KDM4E 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.